Distinguished in Embryonal Tumor with Multilayered Rosettes

Giuseppe Barone

Great Ormond Street Hospital
London, ENG, GB 
Distinguished in Embryonal Tumor with Multilayered Rosettes
Great Ormond Street Hospital
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Giuseppe Barone practices in London, United Kingdom. Mr. Barone is rated as a Distinguished expert by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Ganglioneuroma, and Ganglioneuroblastoma.

His clinical research consists of co-authoring 33 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 25 articles and participated in 1 clinical trial in the study of Embryonal Tumor with Multilayered Rosettes.

Gender
Male

Locations

Great Ormond Street Hospital
London, ENG, United Kingdom
Other Locations
Sutton Upon Derwent, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2025
Intervention Type: Drug
Study Drugs: LY3295668 Erbumine, Topotecan, Cyclophosphamide
Study Phase: Phase 1

33 Total Publications

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Barone's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile